Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...

The Food and Drug Administration has granted Alembic permission for Dabigatran Etexilate Capsules, 110 mg, which is the generic of Boehringer Ingelheim’s Pradaxa. Dabigatran Etexilate capsules 110 mg ...

Alembic has received the Food and Drug Administration’s permission for Dabigatran Etexilate Capsules, 75 mg and 150 mg and tentative approval for Dabigatran Etexilate Capsules, 110 mg. The approved ...

Pradaxa (dabigatran) is a prescription drug that’s used to treat and help prevent blood clots. This drug can interact with other medications. For example, Pradaxa can interact with ibuprofen (Advil) ...

Pradaxa (dabigatran) is a brand-name drug that’s prescribed to help treat or prevent blood clots. The medication is available in these forms: oral pellets and oral capsules. The cost of Pradaxa with ...

Ascend Laboratories has recalled 10 lots of Dabigatran Etexilate capsules, used to lower the risk of blood clots and strokes, after finding the nitrosamine in the drug was above the FDA’s acceptable ...

Pradaxa (dabigatran etexilate) is prescribed to lower the risk of blood clots in specific situations. The drug comes as an oral capsule and oral pellets. It’s usually taken once or twice per day ...

It was not safe to combine dabigatran (Pradaxa) with P-glycoprotein (P-gp) inhibitors in people with atrial fibrillation (Afib), even when they had normal kidney function, researchers determined from ...

The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 ...

Please provide your email address to receive an email when new articles are posted on . There was no significant difference between dabigatran and aspirin in preventing recurrent stroke in patients ...

Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban ...

In two trials exploring potential new indications, dabigatran (Pradaxa; Boehringer Ingelheim) failed to show significant advantages over standard treatments for embolic stroke of undetermined source ...